CARsgen Therapeutics Announces 2025 Annual Results

Core Insights - CARsgen Therapeutics has reported significant advancements in its CAR T-cell therapy pipeline, including the acceptance of New Drug Applications for its products and strategic collaborations to enhance manufacturing capabilities [1][2]. Business Highlights - CARsgen has entered into strategic cooperation agreements to establish a commercial manufacturing base for CAR T-cell products in Shanghai [1]. - The company has developed the CARvivo™ platform for in vivo CAR T-cell products and is advancing multiple allogeneic CAR-T products targeting various diseases [1][2]. - The National Medical Products Administration (NMPA) of China has accepted the New Drug Application for satri-cel, which is expected to be approved in the first half of 2026 [1][2]. - In 2025, CARsgen received 218 confirmed orders for zevor-cel from Huadong Medicine, and the product was included in China's Commercial Health Insurance Innovative Drug Catalogue [1]. Financial Highlights - CARsgen's revenue for 2025 was approximately RMB125.7 million, primarily from zevor-cel, with a gross profit of around RMB80 million [1]. - The net loss for 2025 was RMB103 million, a decrease of approximately 87% from RMB798 million in 2024 [1]. - Cash and cash equivalents were around RMB1,123 million as of December 31, 2025, with expectations to maintain at least RMB1,000 million by the end of 2026 [1]. Product Development - Zevor-cel, an autologous CAR T-cell product, has shown rapid sales growth and is approved for treating relapsed or refractory multiple myeloma [1][2]. - Satri-cel is the first CAR T-cell therapy for solid tumors to reach NDA stage globally, demonstrating significant clinical benefits in trials [2]. - CARsgen is advancing multiple allogeneic CAR T-cell candidates, including CT0596 and CT1190B, targeting various hematologic malignancies and autoimmune diseases [2]. Manufacturing Expansion - CARsgen is enhancing its manufacturing capabilities through a strategic investment of up to RMB370 million to support the commercialization of its CAR T-cell therapies [2][3]. - The collaboration with Shanghai Jingong Enterprise Development Co., Ltd. aims to establish a manufacturing base that meets international standards [2].